Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119177
Author
Bando, Hiroshi Tokushima University|Medical Research|Japan Low Carbohydrate Diet Promotion Association|Yoshinogawa Hospital KAKEN Search Researchers
Ogawa, H Yoshinogawa Hospital
Kobayashi, H Yoshinogawa Hospital
Nakanishi, S Yoshinogawa Hospital
Watanabe, O Yoshinogawa Hospital
Keywords
Imeglimin (Twymeeg)
Glubes (mitiglinide/voglibose)
EquMet (Vildagliptin/Metformin)
Trials of IMeglimin for Efficacy and Safety (TIMES)
Oral hypoglycemic agent (OHA)
Content Type
Journal Article
Description
For latest topic, imeglimin (Twymeeg) shows clinical efficacy among several oral hypoglycemic agents (OHAs). The case is 79-year-old male with Type 2 diabetes (T2D) for long. He had hypoglycemic episode in Sept 2022, and then Glubes (mitiglinide/voglibose) was discontinued and EquMet (Vildagliptin/Metformin) was started in Oct 2022. His HbA1c increased to 8.3% in Jan 2023, followed by initiating Twymeeg. Clinical efficacy showed satisfactory degree for glucose variability as 7.3% for 8 weeks. He has body mass index (BMI) 22.0 kg/m2, and daily exercise habit. These factors may contribute diabetic improvement in addition to clinical efficacy of EquMet and Twymeeg.
Journal Title
SunText Review of Endocrine Care
ISSN
27715469
Publisher
SunText Reviews
Volume
2
Issue
1
Start Page
109
Published Date
2023-03-21
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences
University Hospital